Novel nanoplatform for oral delivery of anti-cancer biomacromolecules

International Journal of Nanotechnology

Volumn 9, Issue 10-12, 2012, Pages 942-960

  Mahidhara, Ganesh ^a   Kanwar, Rupinder K ^a   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Alginate; Anti cancer proteins; Ceramic nano cores; Chitosan; Endocytosis and transcytosis; Lactoferrin; Nano carriers; Oral drug delivery

Indexed keywords

ALGINATE; CELL CULTURE; CERAMIC MATERIALS; CHITOSAN; CONTROLLED DRUG DELIVERY; DIGESTIVE SYSTEM; DISEASES; MAMMALS; MOLECULAR BIOLOGY; NANOPARTICLES; NUCLEIC ACIDS; PROTEINS;

ANTI-CANCER PROTEINS; CERAMIC NANO CORES; ENDOCYTOSIS AND TRANSCYTOSIS; LACTOFERRIN; NANO-CARRIERS; ORAL DRUG DELIVERY;

TARGETED DRUG DELIVERY;

EID: 84867289186     PISSN: 14757435     EISSN: None     Source Type: Journal    
DOI: 10.1504/IJNT.2012.049457     Document Type: Article

References (52)

1. Aznavoorian, S., Murphy, A.N., Stetler-Stevenson, W.G. and Liotta, L.A. (1993) 'Molecular aspects of tumor cell invasion and metastasis', Cancer, Vol. 71, No. 4, pp.1368-1383.
2. Folkman, J. (1995) 'Angiogenesis in cancer, vascular, rheumatoid and other disease', Nat. Med., Vol. 1, No. 1, pp.27-31.
3. Kalluri, R. (2003) 'Basement membranes: structure, assembly and role in tumour angiogenesis', Nat. Rev. Cancer, Vol. 3, No. 6, pp.422-433.
4. Ruoslahti, E. (2002) 'Specialization of tumour vasculature', Nat. Rev. Cancer, Vol. 2, No. 2, pp.83-90.
5. Jiang, H., Tao, W., Zhang, M., Pan, S., Kanwar, J.R. and Sun, X. (2010) 'Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice', Cancer Invest., Vol. 28, No. 1, pp.74-84.
6. Kanwar, J.R., Kanwar, R.K., Burrow, H. and Baratchi, S. (2009) 'Recent advances on the roles of NO in cancer and chronic inflammatory disorders', Curr. Med. Chem., Vol. 16, No. 19, pp.2373-2394.
7. Luo, L., Qiao, H., Meng, F., Dong, X., Zhou, B., Jiang, H., Kanwar, J.R., Krissansen, G.W. and Sun, X. (2006) 'Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas', Int. J. Cancer, Vol. 118, No. 7, pp.1823-1830.
8. Sun, X., Qiao, H., Jiang, H., Zhi, X., Liu, F., Wang, J., Liu, M., Dong, D., Kanwar, J.R., Xu, R. and Krissansen, G.W. (2004) 'Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors', Cancer Gene Ther., Vol. 12, No. 1, pp.35-45.
9. Kanwar, R.K., Cheung, C.H.A., Chang, J-Y. and Kanwar, J.R. (2010) 'Recent advances in anti-survivin treatments for cancer', Curr. Med. Chem., Vol. 17, No. 15 (in Press).
10. Bhargava, P., Marshall, J.L., Rizvi, N., Dahut, W., Yoe, J., Figuera, M., Phipps, K., Ong, V.S., Kato, A. and Hawkins, M.J. (1999) 'A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer', Clin. Cancer Res., Vol. 5, No. 8, pp.1989-1995.
11. Cretton-Scott, E., Placidi, L., McClure, H., Anderson, D.C. and Sommadossi, J-P. (1996) 'Pharmacokinetics and metabolism of O-(chloroacetyl- carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys', Cancer Chemother. Pharmacol., Vol. 38, No. 2, pp.117-122.
12. Gerrits, C.J., Burris, H., Schellens, J.H., Eckardt, J.R., Planting, A.S., van der Burg, M.E., Rodriguez, G.I., Loos, W.J., van Beurden, V., Hudson, I., Fields, S., Von Hoff, D.D. and Verweij, J. (1998) 'Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors', Clin. Cancer Res., Vol. 4, No. 5, pp.1153-1158.
13. Zeng, F., Lee, H. and Allen, C. (2006) 'Epidermal growth factor-conjugated poly(ethylene glycol)-block- poly(Î-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics', Bioconjugate Chem., Vol. 17, No. 2, pp.399-409.
14. Kim, J.H., Kim, Y.S., Park, K., Kang, E., Lee, S., Nam, H.Y., Kim, K., Park, J.H., Chi, D.Y., Park, R.W., Kim, I.S., Choi, K. and Chan Kwon, I. (2008) 'Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy', Biomaterials, Vol. 29, No. 12, pp.1920-1930.
15. Kumar Malik, D., Baboota, S., Ahuja, A., Hasan, S. and Ali, J. (2007) 'Recent advances in protein and peptide drug delivery systems', Curr. Drug Delivery, Vol. 4, No. 2, pp.141-151.
16. Jain, S.K. and Jain, A. (2008) 'Target-specific drug release to the colon', Expert Opin. Drug Delivery, Vol. 5, No. 5, pp.483-498.
17. Zhou, X.H. and Li Wan Po, A. (1991) 'Peptide and protein drugs: I. Therapeutic applications, absorption and parenteral administration', Int. J. Pharm., Vol. 75, Nos. 2-3, pp.97-115.
18. Zhang, L., Gu, F.X., Chan, J.M., Wang, A.Z., Langer, R.S. and Farokhzad, O.C. (2007) 'Nanoparticles in medicine: therapeutic applications and developments', Clin. Pharmacol. Ther., Vol. 83, No. 5, pp.761-769.
19. Nishiyama, N. (2007) 'Nanomedicine: nanocarriers shape up for long life', Nat. Nanotechnol., Vol. 2, No. 4, pp.203-204.
20. Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R. and Langer, R. (2007) 'Nanocarriers as an emerging platform for cancer therapy', Nat. Nanotechnol., Vol. 2, No. 12, pp.751-760
21. Duncan, R. (2006) 'Polymer conjugates as anticancer nanomedicines', Nat. Rev. Cancer, Vol. 6, No. 9, pp.688-701.
22. Sanhai, W.R., Sakamoto, J.H., Canady, R. and Ferrari, M. (2008) 'Seven challenges for nanomedicine', Nat. Nanotechnol., Vol. 3, No. 5, pp.242-244.
23. Liam, M., Kanwar, R.K., Shufeng, Z., Raj, B., Vasu, P. and Kanwar, J.R. (2009) 'Applications of nanomedicine in antibacterial medical therapeutics and diagnostics', The Open Tropical Medicine Journal, Vol. 3, No. 1, pp.1-9.
24. Baratchi, S., Kanwar, R.K., Khoshmanesh, K., Vasu, P., Ashok, C., Hittu, M., Parratt, A., Krishnakumar, S., Sun, X., Sahoo, S.K. and Kanwar, J.R. (2009) 'Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases', Curr. Nanosci., Vol. 5, No. 1. pp.15-25.
25. Kanwar, J.R., Mahidhara, G. and Kanwar, R.K. (2009) 'Recent advances in nanoneurology for drug delivery to the brain', Curr. Nanosci., Vol. 5, No. 4, pp.1573-4137.
26. Matsumura, Y. and Maeda, H. (1986) 'A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs', Cancer Res., Vol. 46, No. 12, Part 1, pp.6387-6392.
27. Sarapa, N., Britto, M., Speed, W., Jannuzzo, M., Breda, M., James, C., Porro, M., Rocchetti, M., Wanders, A., Mahteme, H. and Nygren, P. (2003) 'Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma', Cancer Chemother. Pharmacol., Vol. 52, No. 5, pp.424-430.
28. Hwang, H-Y., Kim, I-S., Kwon, I.C. and Kim, Y-H. (2008) 'Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles', J. Controlled Release, Vol. 128, No. 1, pp.23-31.
29. Benny, O., Fainaru, O., Adini, A., Cassiola, F., Bazinet, L., Adini, I., Pravda, E., Nahmias, Y., Koirala, S., Corfas, G., D'Amato, R.J. and Folkman, J. (2008) 'An orally delivered small-molecule formulation with antiangiogenic and anticancer activity', Nat. Biotechnol., Vol. 26, No. 7, pp.799-807.
30. Zhang, L., Sun, M., Guo, R., Jiang, Z., Liu, Y., Jiang, X. and Yang, C. (2006) 'Chitosan surface-modified hydroxycamptothecin loaded nanoparticles with enhanced transport across Caco-2 cell monolayer', J. Nanosci. Nanotechnol., Vol. 6, No. 10, pp.2912-2920.
31. Balakrishnan, P., Lee, B.J., Oh, D.H., Kim, J.O., Lee, Y.I., Kim, D.D., Jee, J.P., Lee, Y.B., Woo, J.S., Yong, C.S. and Choi, H.G. (2009) 'Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems', Int. J. Pharm., Vol. 374, Nos. 1-2, pp.66-72.
32. Wang, A. and Li, S. (2008) 'Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect', BMC Biotech., Vol. 8, No. 1, p.46.
33. Howard, K.A., Paludan, S.R., Behlke, M.A., Besenbacher, F., Deleuran, B. and Kjems, J. (2008) 'Chitosan/siRNA Nanoparticle-mediated TNF-[alpha] knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model', Mol. Ther., Vol. 17, No. 1, pp.162-168.
34. Yadav, S., van Vlerken, L., Little, S. and Amiji, M. (2009) 'Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells', Cancer Chemother. Pharmacol., Vol. 63, No. 4, pp.711-722.
35. Zhang, Z., Lee, S., Gan, C. and Feng, S-S. (2008) 'In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy', Pharm. Res., Vol. 25, No. 8, pp.1925-1935.
36. Feng, S-S., Mei, L., Anitha, P., Gan, C.W. and Zhou, W. (2009) 'Poly (lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel', Biomaterials, Vol. 30, No. 19, pp.3297-3306.
37. Rawat, M., Singh, D., Saraf, S. and Saraf, S. (2008) 'Development and in vitro evaluation of alginate gel encapsulated, chitosan-coated ceramic nanocores for oral delivery of enzyme', Drug Dev. Ind. Pharm., Vol. 34, No. 2, pp.181-188.
38. Lammel, A., Schwab, M., Slotta, U., Winter, G. and Scheibel, T. (2008) 'Processing conditions for the formation of spider silk microspheres', ChemSusChem., Vol. 1, No. 5, pp.413-416.
39. Slotta, U.K., Rammensee, S., Gorb, S. and Scheibel, T. (2008) 'An engineered spider silk protein forms Microspheres13', Angew. Chem. Int. Ed., Vol. 47, No. 24, pp.4592-4594.
40. Gupta, I., Sehgal, R., Kanwar, R.K., Sehgal, A. and Kanwar, J.R. (2009) 'Recent advances of metal binding protein lactoferrin as an anti- microbial agent', Curr. Bioact. Compd., Vol. 5, No. 3, pp.226-233.
41. Kanwar, J.R., Palmano, K.P., Sun, X., Kanwar, R.K., Gupta, R., Haggarty, N., Rowan, A., Ram, S. and Krissansen, G.W. (2008) "Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy', Immunol. Cell Biol., Vol. 86, No. 3, pp.277-288.
42. Kanwar, J. and Kanwar, R. (2009) 'Gut health immunomodulatory and anti-inflammatory functions of gut enzyme digested high protein micro-nutrient dietary supplement-Enprocal', BMC Immunol., Vol. 10, No. 1, p.7.
43. Kossovsky, N., Gelman, A., Rajguru, S., Nguyen, R., Sponsler, E., Hnatyszyn, H.J., Chow, K., Chung, A., Torres, M., Zemanovich, J., Crowder, J., Bamajian, P., Ly, K., Philipose, J., Ammons, D., Anderson, S., Goodwin, C., Soliemanzadeh, P., Yao, G. and Wei, K. (1996) 'Control of molecular polymorphisms by a structured carbohydrate/ceramic delivery vehicle - aquasomes', J. Controlled Release, Vol. 39, Nos. 2-3, pp.383-388.
44. Cherian, A.K., Rana, A.C. and Jain, S.K. (2000) 'Self-assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin', Drug Develop. Ind. Pharm., Vol. 26, No. 4, pp.459-463.
45. Yuan, W., Dong, H., Li, C.M., Cui, X., Yu, L., Lu, Z. and Zhou, Q. (2007) 'pH-controlled construction of chitosan/alginate multilayer film: characterization and application for antibody immobilization', Langmuir, Vol. 23, No. 26, pp.13046-13052.
46. Pasqualini, R., Koivunen, E. and Ruoslahti, E. (1997) '[alpha]v Integrins as receptors for tumor targeting by circulating ligands', Nat. Biotechol., Vol. 15, No. 6, pp.542-546.
47. Kanwar, J.R., Shen, W.P., Kanwar, R.K., Berg, R.W. and Krissansen, G.W. (2001) 'Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy', J. Natl. Cancer Inst., Vol. 93, No. 20, pp.1541-1552.
48. Ryan, B.M., O'Donovan, N. and Duffy, M.J. (2009) 'Survivin: a new target for anti-cancer therapy', Cancer Treatment Reviews, Vol. 35, No. 7, pp.553-562.
49. Haubner, R., Wester, H.J., Reuning, U., Senekowitsch-Schmidtke, R., Diefenbach, B., Kessler, H., Stocklin, G. and Schwaiger, M. (1999) 'Radio labeled {alpha}v{beta}3 integrin antagonists: a new class of tracers for tumor targeting', J. Nucl. Med., Vol. 40, No. 6, pp.1061-1071.
50. Sivolapenko, G.B., Skarlos, D., Pectasides, D., Stathopoulou, E., Milonakis, A., Sirmalis, G., Stuttle, A., Courtenay-Luck, N.S., Konstantinides, K. and Epenetos, A.A. (1998) 'Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide', Eur. J. Nucl. Med. Mol. Imag., Vol. 25, No. 10, pp.1383-1389.
51. Kobayashi, H. and Lin, P.C. (2006) 'Nanotechnology for antiangiogenic cancer therapy', Nanomed., Vol. 1, No. 1, pp.17-22.
52. Chen, H. and Langer, R. (1998) 'Oral particulate delivery: status and future trends', Adv. Drug Delivery Rev., Vol. 34, Nos. 2-3, pp.339-350.